Stocktoria
Zhengye Biotechnology Holding Ltd ZYBT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2025-01-07
Zhengye Biotechnology Holding Ltd statistics & valuation
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Gross margin | 20.5% | 6.7% | 55.5% |
| Operating margin | -60.6% | 1.2% | 21.3% |
| Net margin | -60.0% | 0.8% | 14.9% |
| FCF margin | 10.6% | 2.0% | 19.3% |
| Return on assets | -16.0% | 2.3% | 6.3% |
| Return on equity | -22.8% | 3.2% | 9.3% |
| Debt / equity | 0.03× | 0.03× | 0.03× |
| Current ratio | 1.14 | 1.31 | 1.26 |
| Revenue growth | -91.1% | -12.0% | — |
Source: SEC EDGAR filings · CIK 0001975641 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.